In our pilot study, we found that a panel of seven biomarkers (dodecanal, 8-hydroxyguanosine, leukotriene C4, α1-antitrypsin, IgA-uromodulin complex, galactose-deficient IgA1, and heparan sulfate) differentiated patients with IgAN from patients with other kidney diseases and healthy controls. Here, IGHA1 is linked to kidney disorder.